ATCOR is the world leader in measuring arterial stiffness and central blood pressure waveforms based on our FDA-cleared and patented technology.  AtCor is a subsidiary of ASX-listed global health tech company CardieX Limited (ASX: CDX). The company's SphygmoCor® technology allows researchers and clinicians to non-invasively measure the central arterial pressure waveform, central aortic pressures, and pulse wave velocity. Central arterial pressure waveform analysis, as measured by the company’s SphygmoCor system, provides clinicians with better prognostic and diagnostic information to determine the need for - and type of intervention - effects which cannot be detected with standard brachial blood pressure measurements. More than 4,500 SphygmoCor® systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company’s technology has been featured in over 1,400 peer-reviewed studies published in leading medical journals and thousands of citations. An Australian-headquartered company, ATCOR Pty Limited's manufacturing and R&D operations are located in Sydney. The American sales subsidiary, ATCOR Medical Inc., is headquartered in Naperville, Illinois. Corporate and business development is located in Irvine, California.